BGL Advises UK Based Cyprotex on Its Acquisition of US Based CeeTox

Brown Gibbons Lang & Company (BGL) today announced its client Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organization (CRO), completed the acquisition of the business and assets of CeeTox, Inc. (“CeeTox”), a division of North American Science Associates, Inc. (NAMSA).  BGL advised Cyprotex in the transaction.

Based in Kalamazoo, Michigan, CeeTox is a CRO specializing in the provision of in vitro toxicological assays and screening data to the personal care, chemical, and pharma / biotech industries. Founded in 2003, CeeTox was acquired in 2005 by NAMSA, a medical research organization supplying expert consulting, clinical and laboratory services to medical device, in vitro diagnostics, and biologics manufacturers. NAMSA retains a license for applying CeeTox’s in vitro toxicology expertise to medical device testing.

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Massachusetts and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech’s to large pharmaceutical companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modeling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, please visit www.cyprotex.com.